University of Groningen

Clinical and biological aspects of multiple myelomaHovenga, Sjoerd

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite fromit. Please check the document version below.

Document VersionPublisher's PDF, also known as Version of record

Publication date:2007

Link to publication in University of Groningen/UMCG research database

Citation for published version (APA):Hovenga, S. (2007). Clinical and biological aspects of multiple myeloma. [s.n.].

CopyrightOther than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of theauthor(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

Take-down policyIf you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediatelyand investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons thenumber of authors shown on this cover page is limited to 10 maximum.

Download date: 03-06-2021

https://research.rug.nl/en/publications/clinical-and-biological-aspects-of-multiple-myeloma(e467aa76-96e4-4f88-bf85-0a97e6f56c2b).html

References

127

References 1. KyleRA&RajkumarSV.Multiple myeloma.

TheNewEnglandJournalofMedicine2004;351:1860-73. 2. JaffeES,HarrisNL,SteinH et al.Pathology and Genetics of Tumours of

Haematopoietic and Lymphoid Tissues.2001; 3. RajkumarSV,KyleRA,TherneauTM et al.Serum free light chain ratio is an

independent risk factor for progression in monoclonal gammopathy of undetermined significance (MGUS).Blood2005;

4. KuehlWM&BergsagelPL.Multiple myeloma: evolving genetic events and host interactions.NatureReviewsCancer2002;2:175-87.

5. HollandJ,TrenknerDA,WassermanTH et al.Plasmacytoma. Treatment results and conversion to myeloma.Cancer1992;69:1513-7.

6. DurieBG&SalmonSE.A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival.Cancer1975;36:842-54.

7. GreippPR,SanMiguelJF,DurieBG et al.International staging system for multiple myeloma.JournalofClinicalOncology2005;23:3412-20.

8. ChildJA&KushwahaMR.Serum beta 2-microglobulin in lymphoproliferative and myeloproliferative diseases.Hematology&Oncology™1984;2:391-401.

9. TienhaaraA,PulkkiK,MattilaK et al.Serum immunoreactive interleukin-6 and C-reactive protein levels in patients with multiple myeloma at diagnosis.BritishJournalofHaematology1994;86:391-3.

10. DewaldGW,KyleRA,HicksGA et al.The clinical significance of cytogenetic studies in 100 patients with multiple myeloma, plasma cell leukemia, or amyloidosis.Blood1985;66:380-90.

11. DurieBG.Cellular and molecular genetic features of myeloma and related disorders.Hematology-OncologyClinicsofNorthAmerica1992;6:463-77.

12. SawyerJR,WaldronJA,JagannathS et al.Cytogenetic findings in 200 patients with multiple myeloma.CancerGeneticsandCytogenetics1995;82:41-9.

13. LaiJL,ZandeckiM,MaryJY et al.Improved cytogenetics in multiple myeloma: a study of 151 patients including 117 patients at diagnosis.Blood1995;85:2490-7.

14. KonigsbergR,ZojerN,AckermannJ et al.Predictive role of interphase cytogenetics for survival of patients with multiple myeloma.JournalofClinicalOncology2000;18:804-12.

15. BarlogieB,EpsteinJ,SelvanayagamP et al.Plasma cell myeloma - new biological insights and advances in therapy.Blood1989;73:865-79.

References

128

16. ZojerN,KonigsbergR,AckermannJ et al.Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization.Blood2000;95:1925-30.

17. ShaughnessyJ,Jr.,TianE,SawyerJ et al.Prognostic impact of cytogenetic and interphase fluorescence in situ hybridization-defined chromosome 13 deletion in multiple myeloma: early results of total therapy II.BritishJournalofHaematology2003;120:44-52.

18. WijdenesJ,VooijsWC,ClementC et al.A plasmocyte selective monoclonal antibody (B-B4) recognizes syndecan-1.BritishJournalofHaematology1996;94:318-23.

19. SeidelC,SundanA,HjorthM et al.Serum syndecan-1: a new independent prognostic marker in multiple myeloma.Blood2000;95:388-92.

20. RawstronAC,DaviesFE,DasGuptaR et al.Flow cytometric disease monitoring in multiple myeloma: the relationship between normal and neoplastic plasma cells predicts outcome after transplantation. Blood2002;100:3095-100.

21. SanMiguelJF,AlmeidaJ,MateoG et al.Immunophenotypic evaluation of the plasma cell compartment in multiple myeloma: a tool for comparing the efficacy of different treatment strategies and predicting outcome.Blood2002;99:1853-6.

22. ChangH,SamieeS,YiQL.Prognostic relevance of CD56 expression in multiple myeloma: A study including 107 cases treated with high-dose melphalan-based chemotherapy and autologous stem cell transplant.LeukemiaandLymphoma2006;47:43-7.

23. IshikawaH,TsuyamaN,MahmoudMS et al.CD19 expression and growth inhibition of tumours in human multiple myeloma.LeukemiaandLymphoma2002;43:613-6.

24. EistererW,BechterO,HilbeW et al.CD44 isoforms are differentially regulated in plasma cell dyscrasias and CD44v9 represents a new independent prognostic parameter in multiple myeloma.LeukemiaResearch2001;25:1051-7.

25. StauderR,vanDrielM,SchwarzlerC et al.Different CD44 splicing patterns define prognostic subgroups in multiple myeloma.Blood1996;88:3101-8.

26. vanDrielM,GunthertU,StauderR et al.CD44 isoforms distinguish between bone marrow plasma cells from normal individuals and patients with multiple myeloma at different stages of disease.Leukemia1998;12:1821-8.

27. vanDrielM,GunthertU,vanKesselAC et al.CD44 variant isoforms are involved in plasma cell adhesion to bone marrow stromal cells.Leukemia2002;16:135-43.

References

129

28. SanMiguelJF,GonzalezM,GasconA et al.Immunophenotypic heterogeneity of multiple myeloma: influence on the biology and clinical course of the disease. Castellano-Leones (Spain) Cooperative Group for the Study of Monoclonal Gammopathies.BritishJournalofHaematology1991;77:185-90.

29. Pellat-DeceunynckC,BatailleR,RobillardN et al. Expression of CD28 and CD40 in human myeloma cells: a comparative study with normal plasma cells.Blood1994;84:2597-603.

30. RobillardN,JegoG,Pellat-DeceunynckC et al.CD28, a marker associated with tumoral expansion in multiple myeloma.ClinicalCancerResearch1998;4:1521-6.

31. GuikemaJEJ,HovengaS,VellengaE et al.CD27 is heterogeneously expressed in multiple myeloma: low CD27 expression in patients with high-risk disease. BritishJournalofHaematology2003;121:36-43.

32. KatayamaY,SakaiA,OueN et al.A possible role for the loss of CD27-CD70 interaction in myelomagenesis.BritishJournalofHaematology2003;120:223-34.

33. ZhanF,HardinJ,KordsmeierB et al.Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells.Blood2002;99:1745-57.

34. HanahanD&WeinbergRA.The hallmarks of cancer.Cell2000;100:57-70. 35. FuldaS,SusinSA,KroemerG et al.Molecular ordering of apoptosis induced by

anticancer drugs in neuroblastoma cells.CancerResearch1998;58:4453-60. 36. HallekM,BergsagelPL,AndersonKC.Multiple myeloma: increasing evidence for

a multistep transformation process.Blood1998;91:3-21. 37. Avet-LoiseauH,FaconT,DavietA et al.14q32 translocations and monosomy 13

observed in monoclonal gammopathy of undetermined significance delineate a multistep process for the oncogenesis of multiple myeloma. Intergroupe Francophone du Myelome.CancerResearch1999;59:4546-50.

38. FonsecaR,BaileyRJ,AhmannGJ et al.Genomic abnormalities in monoclonal gammopathy of undetermined significance.Blood2002;100:1417-24.

39. MitsiadesN,MitsiadesCS,PoulakiV et al.Intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human multiple myeloma cells.Blood2002;99:2162-71.

40. GriffithTS,ChinWA,JacksonGC et al.Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells.JournalofImmunology1998;161:2833-40.

41. LuoX,BudihardjoI,ZouH et al.Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors.Cell1998;94:481-90.

References

130

42. ShipmanCM&CroucherPI.Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells.CancerResearch2003;63:912-6.

43. SuzukiM,YouleRJ,TjandraN.Structure of Bax: coregulation of dimer formation and intracellular localization.Cell2000;103:645-54.

44. WangX.The expanding role of mitochondria in apoptosis.GenesandDevelopment2001;15:2922-33.

45. CoryS&AdamsJM.The Bcl2 family: regulators of the cellular life-or-death switch.NatureReviewsCancer2002;2:647-56.

46. SaitoM,KorsmeyerSJ,SchlesingerPH.BAX-dependent transport of cytochrome c reconstituted in pure liposomes.NatureCellBiology2000;2:553-5.

47. HuangDC&StrasserA.BH3-Only proteins-essential initiators of apoptotic cell death.Cell2000;103:839-42.

48. OltvaiZN,MillimanCL,KorsmeyerSJ.Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death.Cell1993;74:609-19.

49. ChengEH,WeiMC,WeilerS et al.Bcl-2, Bcl-X(L) sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis. MolecularCell2001;8:705-11.

50. WeiMC,ZongWX,ChengEH et al.Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death.Science2001;292:727-30.

51. LetaiA,BassikMC,WalenskyLD et al.Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. CancerCell2002;2:183-92.

52. NakamuraK,Bossy-WetzelE,BurnsK et al.Changes in endoplasmic reticulum luminal environment affect cell sensitivity to apoptosis.JournalofCellBiology2000;150:731-40.

53. GauthierER,PicheL,LemieuxG et al.Role of Bcl-X(L) in the control of apoptosis in murine myeloma cells.CancerResearch1996;56:1451-6.

54. Miguel-GarciaA,OreroT,MatutesE et al.Bcl-2 expression in plasma cells from neoplastic gammopathies and reactive plasmacytosis: a comparative study. Haematologica1998;83:298-304.

55. JourdanM,VeyruneJL,VosJD et al.A major role for Mcl-1 antiapoptotic protein in the IL-6-induced survival of human myeloma cells.Oncogene2003;22:2950-9.

References

131

56. DerenneS,MoniaB,DeanNM et al.Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells. Blood2002;100:194-9.

57. ZhangB,GojoI,FentonRG.Myeloid cell factor-1 is a critical survival factor for multiple myeloma.Blood2002;99:1885-93.

58. Catlett-FalconeR,LandowskiTH,OshiroMM et al.Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells.Immunity1999;10:105-15.

59. PuthierD,DerenneS,BarilleS et al.Mcl-1 and Bcl-xL are co-regulated by IL-6 in human myeloma cells.BritishJournalofHaematology1999;107:392-5.

60. Quintanilla-MartinezL,KremerM,SpechtK et al.Analysis of signal transducer and activator of transcription 3 (Stat 3) pathway in multiple myeloma: Stat 3 activation and cyclin D1 dysregulation are mutually exclusive events.AmericanJournalofPathology2003;162:1449-61.

61. TzungSP,KimKM,BasanezG et al.Antimycin A mimics a cell-death-inducing Bcl-2 homology domain 3.NatureCellBiology2001;3:183-91.

62. Valentin-OpranA,CharhonSA,MeunierPJ et al.Quantitative histology of myeloma-induced bone changes.BritishJournalofHaematology1982;52:601-10.

63. BatailleR,ChappardD,MarcelliC et al.Mechanisms of bone destruction in multiple myeloma: the importance of an unbalanced process in determining the severity of lytic bone disease.JournalofClinicalOncology1989;7:1909-14.

64. BatailleR,ChappardD,MarcelliC et al.Recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of human multiple myeloma.JournalofClinicalInvestigation1991;88:62-6.

65. LaceyDL,TimmsE,TanHL et al.Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.Cell1998;93:165-76.

66. SimonetWS,LaceyDL,DunstanCR et al.Osteoprotegerin: a novel secreted protein involved in the regulation of bone density.Cell1997;89:309-19.

67. GiulianiN,BatailleR,ManciniC et al.Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment.Blood2001;98:3527-33.

68. PearseRN,SordilloEM,YaccobyS et al.Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression.ProceedingsoftheNationalAcademyofSciencesoftheUnitedStatesofAmerica2001;98:11581-6.

References

132

69. RouxS,MeigninV,QuillardJ et al.RANK (receptor activator of nuclear factor-kappaB) and RANKL expression in multiple myeloma.BritishJournalofHaematology2002;117:86-92.

70. GiulianiN,CollaS,SalaR et al.Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease.Blood2002;100:4615-21.

71. CroucherPI,ShipmanCM,LippittJ et al.Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma.Blood2001;98:3534-40.

72. YaccobyS,PearseRN,JohnsonCL et al.Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity.BritishJournalofHaematology2002;116:278-90.

73. HanJH,ChoiSJ,KuriharaN et al.Macrophage inflammatory protein-1alpha is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor kappaB ligand.Blood2001;97:3349-53.

74. AbeM,HiuraK,WildeJ et al.Role for macrophage inflammatory protein (MIP)-1α and MIP-1β in the development of osteolytic lesions in multiple myeloma. Blood2002;100:2195-202.

75. TarteK,deVosJ,ThykjaerT et al.Generation of polyclonal plasmablasts from peripheral blood B cells: a normal counterpart of malignant plasmablasts.Blood2002;100:1113-22.

76. KatagiriM,HakedaY,ChikazuD et al.Mechanism of stimulation of osteoclastic bone resorption through Gas6/Tyro 3, a receptor tyrosine kinase signaling, in mouse osteoclasts.JournalofBiologicalChemistry2001;276:7376-82.

77. TianE.Elevated expression of WNT signaling antagonists DKK1 and FrzB by malignant plasma cells is strongly associated with lytic bone disease in myeloma. TheHematologyJournal2003;S19.

78. vanCampB,DurieBG,SpierC et al.Plasma cells in multiple myeloma express a natural killer cell-associated antigen: CD56 (NKH-1; Leu-19).Blood1990;76:377-82.

79. ElySA&KnowlesDM.Expression of CD56/neural cell adhesion molecule correlates with the presence of lytic bone lesions in multiple myeloma and distinguishes myeloma from monoclonal gammopathy of undetermined significance and lymphomas with plasmacytoid differentiation. AmericanJournalofPathology2002;160:1293-9.

References

133

80. Pellat-DeceunynckC,BarilleS,JegoG et al.The absence of CD56 (NCAM) on malignant plasma cells is a hallmark of plasma cell leukemia and of a special subset of multiple myeloma.Leukemia1998;12:1977-82.

81. BarilleS,ColletteM,BatailleR et al.Myeloma cells upregulate interleukin-6 secretion in osteoblastic cells through cell-to-cell contact but downregulate osteocalcin.Blood1995;86:3151-9.

82. BergsagelDE.Phase II trials of mitomycin C, AB-100, NSC-1026, L-sarcolysin, and meta-sarcolysin, in the treatment of multiple myeloma.CancerChemother.Rep.1962;16:261-6.

83. BarlogieB,AlexanianR,JagannathS.Plasma cell dyscrasias.JournaloftheAmericanMedicalAssociation1992;268:2946-51.

84. GregoryWM,RichardsMA,MalpasJS.Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials.JournalofClinicalOncology1992;10:334-42.

85. RajkumarSV.A randomised phase III trial of thalidomide plus dexamethasone versus dexamethasone in newly diagnosed multiple myeloma (E1A00): a trial coordinated by the Eastern Cooperative Oncology Group.ProceedingsoftheAmericanSocietyofClinicalOncology2004;558.

86. WeberD,RankinK,GavinoM et al.Thalidomide alone or with dexamethasone for previously untreated multiple myeloma.JournalofClinicalOncology2003;21:16-9.

87. DimopoulosMA,AnagnostopoulosA,WeberD.Treatment of plasma cell dyscrasias with thalidomide and its derivatives.JournalofClinicalOncology2003;21:4444-54.

88. RajkumarSV,HaymanS,GertzMA et al.Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma.JournalofClinicalOncology2002;20:4319-23.

89. CavoM,ZamagniE,TosiP et al.Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma.Blood2005;106:35-9.

90. LeBlancR,CatleyLP,HideshimaT et al.Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. CancerResearch2002;62:4996-5000.

91. MitchellBS.The proteasome - an emerging therapeutic target in cancer.TheNewEnglandJournalofMedicine2003;348:2597-8.

References

134

92. RajkumarSV,RichardsonPG,HideshimaT et al.Proteasome inhibition as a novel therapeutic target in human cancer.JournalofClinicalOncology2005;23:630-9.

93. JagannathS,BarlogieB,BerensonJ et al.A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma.BritishJournalofHaematology2004;127:165-72.

94. RichardsonPG,BarlogieB,BerensonJR et al.A phase 2 study of bortezomib in relapsed, refractory myeloma.TheNewEnglandJournalofMedicine2003;348:2609-17.

95. RichardsonPG,SonneveldP,SchusterMW et al.Bortezomib or high-dose dexamethasone for relapsed multiple myeloma.TheNewEnglandJournalofMedicine2005;352:2487-98.

96. JagannathS,DurieBG,WolfJ et al.Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. BritishJournalofHaematology2005;129:776-83.

97. OakerveeHE,PopatR,CurryN et al.PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma.BritishJournalofHaematology2005;129:755-62.

98. RichardsonPG,SchlossmanRL,WellerE et al.Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.Blood2002;100:3063-7.

99. RichardsonPG.A multi-center randomized phase II study to evaluate the efficacy and safety of two CC-5013 dose regimens, when used alone or in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma.Blood2002;100:104a(abstract).

100. OkenMM,HarringtonDP,AbramsonN et al.Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: results of Eastern Cooperative Oncology Group Study E2479.Cancer1997;79:1561-7.

101. PalumboA,BringhenS,CaravitaT et al.Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial.TheLancet2006;367:825-31.

102. PalumboA.A prospective randomized trial of oral melphalan, prednisone, thalidomide (MPT) vs oral melphalan, prednisone (MP): an interim analysis. Blood2004;104:63a.

References

135

103. MateosMV,HernandezJM,HernandezMT et al.Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study.Blood2006;108:2165-72.

104. FaconT,MaryJY,PegourieB et al.Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy.Blood2006;107:1292-8.

105. AttalM,HarousseauJL,StoppaAM et al.A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myelome.TheNewEnglandJournalofMedicine1996;335:91-7.

106. ChildJA,MorganGJ,DaviesFE et al.High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. TheNewEnglandJournalofMedicine2003;348:1875-83.

107. BladeJ,VesoleDH,GertzM.High-dose therapy in multiple myeloma.Blood2003;102:3469-70.

108. FermandJP&BrechignacS.The role of autologous stem cell transplantation in the management of multiple myeloma.PathologieBiologie(Paris)1999;47:199-202.

109. BarlogieB,ShaughnessyJ,TricotG et al.Treatment of multiple myeloma.Blood2004;103:20-32.

110. SegerenCM,SonneveldP,vanderHoltB et al.Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study.Blood2003;101:2144-51.

111. MoreauP,FaconT,AttalM et al.Comparison of 200 mg/m2 melphalan and 8 Gy total body irradiation plus 140 mg/m2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trial.Blood2002;99:731-5.

112. FermandJP,RavaudP,ChevretS et al.High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood1998;92:3131-6.

113. BarlogieB,JagannathS,DesikanKR et al.Total therapy with tandem transplants for newly diagnosed multiple myeloma.Blood1999;93:55-65.

References

136

114. TricotG,SpencerT,SawyerJ et al.Predicting long-term (> or = 5 years) event-free survival in multiple myeloma patients following planned tandem autotransplants. BritishJournalofHaematology2002;116:211-7.

115. AttalM,HarousseauJL,FaconT et al.Single versus double autologous stem-cell transplantation for multiple myeloma.TheNewEnglandJournalofMedicine2003;349:2495-502.

116. CavoM.Single versus tandem autologous transplants in multiple myeloma: Italian experience (abstract).TheHematologyJournal2003;4:560.

117. BarlogieB.High dose therapy versus conventional chemotherapy for newly diagnosed multiple myeloma: historical comparison of total therapy I versus standard SWOG trials and US intergroup trial SWOG 9321.TheHematologyJournal2003;4:S57.

118. CorradiniP,VoenaC,TarellaC et al.Molecular and clinical remissions in multiple myeloma: role of autologous and allogeneic transplantation of hematopoietic cells.JournalofClinicalOncology1999;17:208-15.

119. LiburaJ,HoffmannT,PasswegJ et al.Graft-versus-myeloma after withdrawal of immunosuppression following allogeneic peripheral stem cell transplantation. BoneMarrowTransplantation1999;24:925-7.

120. SalamaM,NevillT,MarcellusD et al.Donor leukocyte infusions for multiple myeloma.BoneMarrowTransplantation2000;26:1179-84.

121. SinghalS,MehtaJ,DesikanR et al.Antitumor activity of thalidomide in refractory multiple myeloma.TheNewEnglandJournalofMedicine1999;341:1565-71.

122. BarlogieB,DesikanR,EddlemonP et al.Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients.Blood2001;98:492-4.

123. KyriakouC,ThomsonK,D’SaS et al.Low-dose thalidomide in combination with oral weekly cyclophosphamide and pulsed dexamethasone is a well tolerated and effective regimen in patients with relapsed and refractory multiple myeloma. BritishJournalofHaematology2005;129:763-70.

124. HovengaS,DaenenSMGJ,deWolfJThM et al.Combined thalidomide and cyclophosphamide treatment for refractory or relapsed multiple myeloma patients: a prospective phase II study.AnnalsofHematology2005;84:311-6.

References

137

125. ZangariM,BarlogieB,BurnsMJ et al.Velcade (V) - thalidomide (T) - dexamethasone (D) for advanced and refractory multiple myeloma (MM): long-term follow-up of phase I-II Trial UARK 2001-37: superior outcome in patients with normal cytogenetics and no prior T.2006;Proceedingsofthe47thAnnualMeetingoftheAmericanSocietyofHematology.Atlanta,Ga(abstract#2552):2005.

126. LudwigH,FritzE,KotzmannH et al.Erythropoietin treatment of anemia associated with multiple myeloma.TheNewEnglandJournalofMedicine1990;322:1693-9.

127. CazzolaM,MessingerD,BattistelV et al.Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin’s lymphoma: dose finding and identification of predictors of response.Blood1995;86:4446-53.

128. DammaccoF,CastoldiG,RodjerS.Efficacy of epoetin alfa in the treatment of anaemia of multiple myeloma.BritishJournalofHaematology2001;113:172-9.

129. OsterborgA,BoogaertsMA,CiminoR et al.Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin’s lymphoma-a randomized multicenter study. The European Study Group of Erythropoietin (Epoetin Beta) Treatment in Multiple Myeloma and Non-Hodgkin’s Lymphoma.Blood1996;87:2675-82.

130. BelchAR,BergsagelDE,WilsonK et al. Effect of daily etidronate on the osteolysis of multiple myeloma.JournalofClinicalOncology1991;9:1397-402.

131. LahtinenR,LaaksoM,PalvaI et al.Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Finnish Leukaemia Group.TheLancet1992;340:1049-52.

132. BerensonJR,LichtensteinA,PorterL et al.Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group.TheNewEnglandJournalofMedicine1996;334:488-93.

133. McCloskeyEV,MacLennanIC,DraysonMT et al.A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. MRC Working Party on Leukaemia in Adults.BritishJournalofHaematology1998;100:317-25.

134. MenssenHD,SakalovaA,FontanaA et al.Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma.JournalofClinicalOncology2002;20:2353-9.

135. ViereckV,EmonsG,LauckV et al.Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts.BiochemicalandBiophysicalResearchCommunications2002;291:680-6.

References

138

136. BerensonJR.Recommendations for zoledronic acid treatment of patients with bone metastases.TheOncologist2005;10:52-62.

137. BadrosA,WeikelD,SalamaA et al.Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors.JournalofClinicalOncology2006;24:945-52.

138. BamiasA,KastritisE,BamiaC et al.Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors.JournalofClinicalOncology2005;23:8580-7.

139. GreippPR.Advances in the diagnosis and management of myeloma.SeminarsinHematology1992;29:24-45.

140. AlexanianR&DimopoulosM.The treatment of multiple myeloma.TheNewEnglandJournalofMedicine1994;330:484-9.

141. CunninghamD,Paz-AresL,GoreME et al.High-dose melphalan for multiple myeloma: long-term follow-up data.JournalofClinicalOncology1994;12:764-8.

142. TricotG,JagannathS,VesoleD et al.Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients.Blood1995;85:588-96.

143. HarousseauJL,AttalM,DivineM et al.Autologous stem cell transplantation after first remission induction treatment in multiple myeloma. A report of the French Registry on Autologous Transplantation in Multiple Myeloma.StemCells1995;13Suppl2:132-9.

144. DemuynckH,DelforgeM,VerhoefG et al.Comparative study of peripheral blood progenitor cell collection in patients with multiple myeloma after single-dose cyclophosphamide combined with rhGM-CSF or rhG-CSF.BritishJournalofHaematology1995;90:384-92.

145. ZentCS,WilsonCS,TricotG et al.Oligoclonal protein bands and Ig isotype switching in multiple myeloma treated with high-dose therapy and hematopoietic cell transplantation.Blood1998;91:3518-23.

146. PascaliE,PezzoliA,ChiarandiniA.Immunofixation: application to the identification of “difficult” monoclonal components.ClinicalChemistry1982;28:1404-5.

147. VellengaE,deWolfJThM,BeentjesJAM et al.Divergent effects of interleukin-4 (IL-4) on the granulocyte colony-stimulating factor and IL-3-supported myeloid colony formation from normal and leukemic bone marrow cells.Blood1990;75:633-7.

References

139

148. BarlogieB,VelasquezWS,AlexanianR et al.Etoposide, dexamethasone, cytarabine, and cisplatin in vincristine, doxorubicin, and dexamethasone-refractory myeloma.JournalofClinicalOncology1989;7:1514-7.

149. JagannathS,BarlogieB,DickeK et al.Autologous bone marrow transplantation in multiple myeloma: identification of prognostic factors.Blood1990;76:1860-6.

150. AttalM,HuguetF,SchlaiferD et al.Intensive combined therapy for previously untreated aggressive myeloma.Blood1992;79:1130-6.

151. CorradiniP,VoenaC,AstolfiM et al.High-dose sequential chemoradiotherapy in multiple myeloma: residual tumor cells are detectable in bone marrow and peripheral blood cell harvests and after autografting.Blood1995;85:1596-602.

152. VellengaE,vanPuttenWL,BoogaertsMA et al.Peripheral blood stem cell transplantation as an alternative to autologous marrow transplantation in the treatment of acute myeloid leukemia?BoneMarrowTransplantation1999;23:1279-82.

153. GerritsenEJ,vanTolMJ,LankesterAC et al.Immunoglobulin levels and monoclonal gammopathies in children after bone marrow transplantation.Blood1993;82:3493-502.

154. HammarströmL&SmithCI.Frequent occurrence of monoclonal gammopathies with an imbalanced light-chain ratio following bone marrow transplantation. Transplantation1987;43:447-9.

155. MitusAJ,SteinR,RappeportJM et al.Monoclonal and oligoclonal gammopathy after bone marrow transplantation.Blood1989;74:2764-8.

156. FischerAM,SimonF,LeDeistF et al.Prospective study of the occurrence of monoclonal gammapathies following bone marrow transplantation in young children.Transplantation1990;49:731-5.

157. HovengaS,deWolfJThM,KlipH et al.Consolidation therapy with autologous stem cell transplantation in plasma cell leukemia after VAD, high-dose cyclophosphamide and EDAP courses: a report of three cases and a review of the literature.BoneMarrowTransplantation1997;20:901-4.

158. GuikemaJEJ,VellengaE,VeenemanJM et al.Multiple myeloma related cells in patients undergoing autologous peripheral blood stem cell transplantation.BritishJournalofHaematology1999;104:748-54.

159. WoodruffRK,MalpasJS,PaxtonAM et al.Plasma cell leukemia (PCL): A report on 15 patients.Blood1978;52:839-45.

160. NoelP&KyleRA.Plasma cell leukemia: an evaluation of response to therapy. AmericanJournalofMedicine1987;83:1062-8.

References

140

161. BernasconiC,CastelliG,PagnuccoG et al.Plasma cell leukemia: a report on 15 patients.EuropeanJournalofHaematology(supplementum)1989;51:76-83.

162. KosmoMA&GaleRP.Plasma cell leukemia.SeminarsinHematology1987;24:202-8.

163. DimopoulosMA,PalumboA,DelasalleKB et al.Primary plasma cell leukaemia. BritishJournalofHaematology1994;88:754-9.

164. McElwainTJ&PowlesRL.High-dose intravenous melphalan for plasma-cell leukaemia and myeloma.TheLancet1983;2:822-4.

165. SuzukiM,KawauchiK,SugiyamaH et al.Primary plasma cell leukemia: a case report of successful responder to a combination chemotherapy of vincristine, doxorubicin and dexamethasone.ActaHaematologica1989;82:95-7.

166. MalhotraH,DhabharBN,SaikiaTK et al.Ifosfamide in plasma cell leukemia: a report of two cases and review of the literature.AmericanJournalofHematology1992;40:226-8.

167. YamagataN,ShimazakiC,GotoH et al.IgE plasma cell leukemia successfully treated with combination VAD (vincristine, doxorubicin, dexamethasone) and MP (melphalan, prednisolone) followed by interferon-alpha.AmericanJournalofHematology1994;45:262-4.

168. OsantoS,MullerHP,SchuitHR et al.Primary plasma cell leukaemia. A case report and a review of the literature.ActaHaematologica1983;70:122-9.

169. MontecuccoC,RiccardiA,MerliniG et al.Complete remission in plasma cell leukaemia.BritishJournalofHaematology1986;62:525-7.

170. DjaldettiM&JoshuaH.Acute plasma cell leukemia. A case report.IsraelMedicalJournal1961;20:109-13.

171. PacilliL,FerraroP,CochiS et al.Plasma cell leukemia: a report on three patients. Tumori1983;69:589-91.

172. ZawadzkiZA,KapadiaS,BarnesAE.Leukemic myelomatosis (plasma cell leukemia).AmericanJournalofClinicalPathology1978;70:605-11.

173. YehKH,LinMT,TangJL et al.Long-term disease-free survival after autologous bone marrow transplantation in a primary plasma cell leukaemia: detection of minimal residual disease in the transplant marrow by third-complementarity-determining region-specific probes.BritishJournalofHaematology1995;89:914-6.

174. BjörkstrandB,LjungmanP,SvenssonH et al.Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case-matched study from the European Group for Blood and Marrow Transplantation.Blood1996;88:4711-8.

References

141

175. JagannathS,VesoleDH,TricotG et al.Hemopoietic stem cell transplants for multiple myeloma.Oncology(WillistonPark,NY)1994;8:89-103.

176. BarlogieB,JagannathS,VesoleDH et al.Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma.Blood1997;89:789-93.

177. TricotG,VesoleDH,JagannathS et al.Graft-versus-myeloma effect: proof of principle.Blood1996;87:1196-8.

178. RajeN,HideshimaT,DaviesFE et al.Tumour cell/dendritic cell fusions as a vaccination strategy for multiple myeloma.BritishJournalofHaematology2004;125:343-52.

179. HideshimaT,ChauhanD,HayashiT.Blockade of IL-6 triggered signaling cascades by PS-341 (Velcade®) via Caspase-dependent downregulation of gp130 in multiple myeloma (MM).Blood2003;102:75A.

180. ChauhanD,UchiyamaH,AkbaraliY et al.Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B.Blood1996;87:1104-12.

181. DamianoJS,CressAE,HazlehurstLA et al.Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines.Blood1999;93:1658-67.

182. GuptaD,LiYZ,LiCJ.β−Lapachone demonstrates activity against drug resistant multple myeloma (MM) cell lines and patient cells.Blood2000;96:307A.

183. AbdallaSH&MahmoudS.Thalidomide in relapsed or refractory multiple myeloma: how much and for how long?LeukemiaandLymphoma2003;44:989-91.

184. AnagnostopoulosA,WeberD,RankinK et al.Thalidomide and dexamethasone for resistant multiple myeloma.BritishJournalofHaematology2003;121:768-71.

185. KeesM,DimouG,SillaberC et al.Low dose thalidomide in patients with relapsed or refractory multiple myeloma.LeukemiaandLymphoma2003;44:1943-6.

186. CelestiL,ClavioM,PoggiA et al.The association of cyclophosphamide and dexamethasone in advanced refractory multiple myeloma patients.Haematologica1997;82:351-3.

187. ManoharanA.Gentle yet effective treatment for elderly patients with refractory or relapsing multiple myeloma.AmericanJournalofHematology2000;65:81-2.

188. BladeJ&EsteveJ.Viewpoint on the impact of interferon in the treatment of multiple myeloma: benefit for a small proportion of patients?MedicalOncology2000;17:77-84.

References

142

189. HanahanD,BergersG,BergslandE.Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice.JournalofClinicalInvestigation2000;105:1045-7.

190. deWeerdtO,vandeDonkNW,VethG et al.Continuous low-dose cyclophosphamide-prednisone is effective and well tolerated in patients with advanced multiple myeloma.TheNetherlandsJournalofMedicine2001;59:50-6.

191. HovengaS,deWolfJThM,GuikemaJEJ et al.Autologous stem cell transplantation in multiple myeloma after VAD and EDAP courses: a high incidence of oligoclonal serum Igs post transplantation.BoneMarrowTransplantation2000;25:723-8.

192. JuliussonG,CelsingF,TuressonI et al.Thalidomide frequently induces good partial remission and best response ever in patients with advanced myeloma and prior high dose melphalan and autotransplant.Blood1999;94:124A.

193. OakerveeHE,McBrideNC,HemmawayCJ.Thalidomide combined with vincristine, adriamycin and dexamethasone (T-VAD) is effective treatment for multiple myeloma and does not prejudice successful stem cell harvesting.Blood2002;100:402A.

194. RajkumarSV&KyleRA.Thalidomide in the treatment of plasma cell malignancies.JournalofClinicalOncology2001;19:3593-5.

195. TosiP,RonconiS,ZamagniE et al.Salvage therapy with thalidomide in multiple myeloma patients relapsing after autologous peripheral blood stem cell transplantation.Haematologica2001;86:409-13.

196. PalumboA,GiacconeL,BertolaA et al.Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma. Haematologica2001;86:399-403.

197. ChungF,PalmerBD,MullerGW et al.Effect of 3-fluorothalidomide and 3-methylthalidomide enantiomers on tumor necrosis factor production and antitumor responses to the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).OncologyResearch2003;14:75-82.

198. MoehlerTM,NebenK,BennerA et al.Salvage therapy for multiple myeloma with thalidomide and CED chemotherapy.Blood2001;98:3846-8.

199. KropffMH,LangN,BispingG et al.Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma.BritishJournalofHaematology2003;122:607-16.

References

143

200. Garcia-SanzR,Gonzalez-PorrasJR,HernandezJM et al.The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed/refractory multiple myeloma.Leukemia2004;18:856-63.

201. BadrosA,MorrisC,ZangariM et al.Thalidomide paradoxical effect on concomitant multiple myeloma and myelodysplasia.LeukemiaandLymphoma2002;43:1267-71.

202. BerensonJR,MaHM,VescioR.The role of nuclear factor-kappaB in the biology and treatment of multiple myeloma.SeminarsinOncology2001;28:626-33.

203. CheungWC&vanNessB.Distinct IL-6 signal transduction leads to growth arrest and death in B cells or growth promotion and cell survival in myeloma cells.Leukemia2002;16:1182-8.

204. HuL,ShiY,HsuJH et al.Downstream effectors of oncogenic ras in multiple myeloma cells.Blood2003;101:3126-35.

205. NiuG,WrightKL,HuangM et al.Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis.Oncogene2002;21:2000-8.

206. PruneriG,PonzoniM,FerreriAJ et al.Microvessel density, a surrogate marker of angiogenesis, is significantly related to survival in multiple myeloma patients. BritishJournalofHaematology2002;118:817-20.

207. BladeJ,SamsonD,ReeceD et al.Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant.BritishJournalofHaematology1998;102:1115-23.

208. ManiotisAJ,FolbergR,HessA et al.Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry.AmericanJournalofPathology1999;155:739-52.

209. WeidnerN,SempleJP,WelchWR et al.Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma.TheNewEnglandJournalofMedicine1991;324:1-8.

210. VermeulenPB,GaspariniG,FoxSB et al.Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation.EuropeanJournalofCancer1996;32A:2474-84.

211. PadroT,RuizS,BiekerR et al.Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia.Blood2000;95:2637-44.

References

144

212. deBontES,RosatiS,JacobsS et al.Increased bone marrow vascularization in patients with acute myeloid leukaemia: a possible role for vascular endothelial growth factor.BritishJournalofHaematology2001;113:296-304.

213. deVosJ,JourdanM,TarteK et al.JAK2 tyrosine kinase inhibitor tyrphostin AG490 downregulates the mitogen-activated protein kinase (MAPK) and signal transducer and activator of transcription (STAT) pathways and induces apoptosis in myeloma cells.BritishJournalofHaematology2000;109:823-8.

214. OgawaM,NishiuraT,OritaniK et al.Cytokines prevent dexamethasone-induced apoptosis via the activation of mitogen-activated protein kinase and phosphatidylinositol 3-kinase pathways in a new multiple myeloma cell line. CancerResearch2000;60:4262-9.

215. ChatterjeeM,HonemannD,LentzschS et al.In the presence of bone marrow stromal cells human multiple myeloma cells become independent of the IL-6/gp130/STAT3 pathway.Blood2002;100:3311-8.

216. VaccaA,RibattiD,PrestaM et al.Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma.Blood1999;93:3064-73.

217. WrobelT,MazurG,SurowiakP et al.Increased expression of vascular endothelial growth factor in bone marrow of multiple myeloma patients.EuropeanJournalofInternalMedicine2003;14:98-100.

218. NiemollerK,JakobC,HeiderU et al.Bone marrow angiogenesis and its correlation with other disease characteristics in multiple myeloma in

stage I versus stage II-III.JournalofCancerResearchandClinicalOncology2003;129:234-8.

219. LemoliRM,FortunaA,GrandeA et al.Expression and functional role of c-kit ligand (SCF) in human multiple myeloma cells.BritishJournalofHaematology1994;88:760-9.

220. HaradaH,KawanoMM,HuangN et al.Phenotypic difference of normal plasma cells from mature myeloma cells.Blood1993;81:2658-63.

221. CameriniD,WalzG,LoenenWA et al.The T cell activation antigen CD27 is a member of the nerve growth factor/tumor necrosis factor receptor gene family.JournalofImmunology1991;147:3165-9.

222. HintzenRQ,deJongR,LensSM et al.CD27: marker and mediator of T-cell activation?ImmunologyToday1994;15:307-11.

223. MaurerD,HolterW,MajdicO et al.CD27 expression by a distinct subpopulation of human B lymphocytes.EuropeanJournalofImmunology1990;20:2679-84.

References

145

224. vanLierRA,BorstJ,VroomTM et al.Tissue distribution and biochemical and functional properties of Tp55 (CD27), a novel T cell differentiation antigen.JournalofImmunology1987;139:1589-96.

225. AgematsuK,HokibaraS,NagumoH et al.CD27: a memory B-cell marker.ImmunologyToday2000;21:204-6.

226. KleinU,RajewskyK,KüppersR.Human immunoglobulin (Ig)M+IgD+ peripheral blood B cells expressing the CD27 cell surface antigen carry somatically mutated variable region genes: CD27 as a general marker for somatically mutated (memory) B cells.JournalofExperimentalMedicine1998;188:1679-89.

227. TangyeSG,LiuYJ,AversaG et al.Identification of functional human splenic memory B cells by expression of CD148 and CD27.JournalofExperimentalMedicine1998;188:1691-703.

228. GoodwinRG,AldersonMR,SmithCA et al.Molecular and biological characterization of a ligand for CD27 defines a new family of cytokines with homology to tumor necrosis factor.Cell1993;73:447-56.

229. HintzenRQ,LensSM,BeckmannMP et al.Characterization of the human CD27 ligand, a novel member of the TNF gene family.JournalofImmunology1994;152:1762-73.

230. LensSM,deJongR,HooibrinkB et al.Phenotype and function of human B cells expressing CD70 (CD27 ligand).EuropeanJournalofImmunology1996;26:2964-71.

231. LensSM,KeehnenRM,vanOersMH et al.Identification of a novel subpopulation of germinal center B cells characterized by expression of IgD and CD70.EuropeanJournalofImmunology1996;26:1007-11.

232. AgematsuK,NagumoH,OguchiY et al.Generation of plasma cells from peripheral blood memory B cells: synergistic effect of interleukin-10 and CD27/CD70 interaction.Blood1998;91:173-80.

233. AgematsuK,HokibaraS,NagumoH et al.Plasma cell generation from B-lymphocytes via CD27/CD70 interaction.LeukemiaandLymphoma1999;35:219-25.

234. LensSM,deJongR,HintzenRQ et al.CD27-CD70 interaction: unravelling its implication in normal and neoplastic B-cell growth.LeukemiaandLymphoma1995;18:51-9.

References

146

235. NagumoH,AgematsuK,ShinozakiK et al.CD27/CD70 interaction augments IgE secretion by promoting the differentiation of memory B cells into plasma cells.JournalofImmunology1998;161:6496-502.

236. FarstadIN,CarlsenH,MortonHC et al.Immunoglobulin A cell distribution in the human small intestine: phenotypic and functional characteristics. Immunology2000;101:354-63.

237. JungJ,ChoeJ,LiL et al.Regulation of CD27 expression in the course of germinal center B cell differentiation: the pivotal role of IL-10.EuropeanJournalofImmunology2000;30:2437-43.

238. vanOersMH,PalsST,EversLM et al.Expression and release of CD27 in human B-cell malignancies.Blood1993;82:3430-6.

239. WillemsP,VerhagenO,SegerenC et al.Consensus strategy to quantitate malignant cells in myeloma patients is validated in a multicenter study. Belgium-Dutch Hematology-Oncology Group.Blood2000;96:63-70.

240. DurieBG,GroganTM,SpierC et al.Myelomonocytic myeloma cell line (LB 84-1).Blood1989;73:770-6.

241. HamiltonMS,BallJ,BromidgeE et al.Characterization of new IgG lambda myeloma plasma cell line (EJM): a further tool in the investigation of the biology of multiple myeloma.BritishJournalofHaematology1990;75:378-84.

242. KarpasA,FisherP,SwirskyD.Human plasmacytoma with an unusual karyotype growing in vitro and producing light-chain immunoglobulin.TheLancet1982;1:931-3.

243. KatagiriS,YonezawaT,KuyamaJ et al.Two distinct human myeloma cell lines originating from one patient with myeloma.InternationalJournalofCancer1985;36:241-6.

244. MatsuokaY,MooreGE,YagiY et al.Production of free light chains of immunoglobulin by a hematopoietic cell line derived from a patient with multiple myeloma.ProceedingsoftheSocietyforExperimentalBiologyandMedicine1967;125:1246-50.

245. NilssonK.Synthesis and secretion of IgE by an established human myeloma cell line.ClinicalandExperimentalImmunology1971;9:785-93.

246. OkunoY,TakahashiT,SuzukiA et al.Establishment and characterization of four myeloma cell lines which are responsive to interleukin-6 for their growth.Leukemia1991;5:585-91.

References

147

247. PegoraroL,MalavasiF,BelloneG et al.The human myeloma cell line LP-1: a versatile model in which to study early plasma-cell differentiation and c-myc activation.Blood1989;73:1020-7.

248. OcqueteauM,OrfaoA,AlmeidaJ et al.Immunophenotypic characterization of plasma cells from monoclonal gammopathy of undetermined significance patients. Implications for the differential diagnosis between MGUS and multiple myeloma.AmericanJournalofPathology1998;152:1655-65.

249. RawstronAC,FentonJA,AshcroftJ et al.The interleukin-6 receptor alpha-chain (CD126) is expressed by neoplastic but not normal plasma cells.Blood2000;96:3880-6.

250. MahmoudMS,FujiiR,IshikawaH et al.Enforced CD19 expression leads to growth inhibition and reduced tumorigenicity.Blood1999;94:3551-8.

251. GutierrezNC,HernandezJM,GarciaJL et al.Differences in genetic changes between multiple myeloma and plasma cell leukemia demonstrated by comparative genomic hybridization.Leukemia2001;15:840-5.

252. JacquotS,KobataT,IwataS et al.CD154/CD40 and CD70/CD27 interactions have different and sequential functions in T cell-dependent B cell responses: enhancement of plasma cell differentiation by CD27 signaling.JournalofImmunology1997;159:2652-7.

253. FonsecaR,BarlogieB,BatailleR et al.Genetics and cytogenetics of multiple myeloma: a workshop report.CancerResearch2004;64:1546-58.

254. ShaughnessyJD,Jr.&BarlogieB.Using genomics to identify high-risk myeloma after autologous stem cell transplantation.BiologyofBloodandMarrowTransplantation2006;12:77-80.

255. CavoM,CelliniC,ZamagniE.Update on high-dose therapy - Italian studies.Haematologica2005;90:suppl1:39.

256. BarlogieB,TricotG,AnaissieE et al.Thalidomide and hematopoietic-cell transplantation for multiple myeloma.TheNewEnglandJournalofMedicine2006;354:1021-30.

257. AttalM,HarousseauJL,LeyvrazS et al. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma.Blood2006;108:3289-94.

258. ZangariM,SiegelE,BarlogieB et al.Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy.Blood2002;100:1168-71.

259. PalumboA,BertolaA,MustoP et al.Oral melphalan, prednisone, and thalidomide for newly diagnosed patients with myeloma.Cancer2005;104:1428-33.

References

148

260. HarousseauJL,AttalM,LeleuX et al.Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study. Haematologica2006;91:1498-505.

261. OrlowskiRZ,VoorheesPM,GarciaRA et al.Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies.Blood2005;105:3058-65.

262. AlexanianR,WangL,WeberD.VTD (Velcade, Thalidomide, Dexamethasone) as primary therapy for newly-diagnosed multiple myeloma.Blood2004;104:98a.

263. SawyersCL.Calculated resistance in cancer.NatureMedicine2005;11:824-5. 264. HusseinMA.Thromboembolism risk reduction in multiple myeloma patients

treated with immunomodulatory drug combinations.ThrombosisandHaemostasis2006;95:924-30.

265. BazR,LiL,Kottke-MarchantK et al.The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma.MayoClinicProceedings2005;80:1568-74.

266. KrauseDS&VanEttenRA. Tyrosine kinases as targets for cancer therapy.TheNewEnglandJournalofMedicine2005;353:172-87.

267. ChesiM,NardiniE,BrentsLA et al.Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3.NatureGenetics1997;16:260-4.

268. TrudelS,StewartAK,RomE et al.The inhibitory anti-FGFR3 antibody, PRO-001, is cytotoxic to t(4;14) multiple myeloma cells.Blood2006;107:4039-46.

269. YaccobyS,LingW,ZhanF et al.Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. Blood2006;

270. LacyMQ,DispenzieriA,GertzMA et al.Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma.MayoClinicProceedings2006;81:1047-53.

271. ShaughnessyJ,Jr.,ZhanF,BarlogieB et al.Gene expression profiling and multiple myeloma.BestPractice&Research.ClinicalHaematology2005;18:537-52.